Media Relations

For Immediate Release

PREGNANT WOMEN WHO DEVELOP LIFE-THREATENING BLOOD CLOTS
SHOULD RECEIVE AGGRESSIVE TREATMENT, RESEARCH SUGGESTS

MIAMI BEACH, Fla. – Pregnant women who develop dangerous blood clots in the leg often forgo the most effective treatment for fear of harming the baby. Yet treatment to remove the clot is not only safe, it can prevent serious problems, including death, suggests research being presented at the 24^th annual International Symposium on Endovascular Therapy (ISET).

Iliofemoral deep vein thrombosis (DVT) – a blood clot that forms deep in the thigh and pelvis – is four to six times more common in pregnant women than those who are not pregnant. This blood clot can break off and travel to the lung causing a potentially deadly condition called pulmonary embolism. When DVT is not treated early and effectively, the clot can become permanent, causing lifelong pain and blood flow problems in the leg. The most effective treatments include the minimally invasive delivery of clot-dissolving drugs directly to the clots to dissolve them, or surgery to remove them.

The study included 11 pregnant women with DVT: Nine were treated with minimally invasive techniques by guiding a tiny tube called a catheter into the clot to deliver clot-dissolving drugs, and two had surgery to remove the clot. Treatment successfully eliminated the clot in all cases. All but one of the pregnancies resulted in a successful birth. One woman in her second trimester miscarried a week after treatment. The woman suffered from antiphospholipid antibody syndrome, which causes the blood to clot abnormally and increases the risk of miscarriage, so the underlying condition likely was the cause of her miscarriage, researchers said. Three of the women had successful subsequent pregnancies.

Pregnant women who develop DVT typically are treated less aggressively with blood thinners, which rarely clears the clot.

“Pulmonary embolism is the leading cause of maternal death in North America,” said Anthony Comerota, M.D., director of the Jobst Vascular Institute at The Toledo Hospital, Ohio. “Physicians should use more effective treatment to prevent these women from having serious life-long problems that can affect their ability to function normally.”

About the International Symposium on Endovascular Therapy (ISET)

Begun in 1989 and led by acclaimed interventionist Barry Katzen, M.D., ISET is attended annually by physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET 2012 will take place Jan. 15–19 at the Fontainebleau Miami Beach. For more information, go to http://www.iset.org.

Editor’s note: Study numbers are current as of Jan. 8, 2012 and may change upon presentation at the ISET meeting.

Copies of ISET 2012 news releases are available online at www.ISETnews.org.

ARTERY DISORDER UNDIAGNOSED IN MILLIONS
Fibromuscular Dysplasia Most Likely To Strike Women, Suggests Registry

MIAMI BEACH, Fla. – The most common disease you’ve never heard of, fibromuscular dysplasia (FMD), frequently goes undetected and can lead to high blood pressure, stroke and aneurysms. Although considered a rare disease, studies suggest close to 4 percent of Americans – more than 5 million people – have FMD. More than 90 percent of sufferers are women, and high blood pressure and headache are the most common symptoms, according to results of an FMD registry being presented at the 24^th annual International Symposium on Endovascular Therapy (ISET).

FMD is an accumulation of fibrous tissue in the arteries – most often those in the kidney or neck – causing them to narrow. About 80 percent of the time, FMD in the kidney arteries causes an alternating bulging and narrowing of the artery that resembles a string of beads.

Researchers at ISET are reporting on 339 registry patients enrolled at seven U.S. centers, 91 percent of whom were female.  More than 95 percent of patients suffered one or more symptoms.  The most common symptoms were:

Of all patients, 19 percent had suffered a tear in an artery, most often in the carotid (neck artery), and 17 percent had suffered an aneurysm, or bulging, most often in the renal (kidney) artery.

FMD location was assessed in 309 patients and was most common in the kidney arteries, affecting 69 percent, followed by the neck arteries, affecting 62 percent. Many patients have FMD in both types of arteries. FMD can occur in any artery.

FMD frequently is undiagnosed because few doctors know to look for it.  It is often found by accident, when people undergo imaging for other conditions, or after a stroke or mini-stroke known as a TIA (transient ischemic attack).

“It’s important to diagnose the disease because 20 percent of people who have FMD have an aneurysm somewhere in their body which could leak or burst, a life-threatening condition,” said Jeffrey W. Olin, D.O., director of vascular medicine at the Mount Sinai School of Medicine, New York. “Doctors need to look for FMD, particularly in patients younger than 35 who have high blood pressure or migraine-type headaches.”

FMD can be diagnosed with ultrasound, angiography, computed tomography angiography (CTA) and magnetic resonance angiography (MRA).  Narrowing of the kidney arteries is treated with angioplasty, in which a tiny tube (catheter) is inserted in the groin artery and advanced to the kidney artery, where a small balloon is inflated to open up the narrowed artery.  Stents are not necessary, nor recommended. If FMD in the kidney arteries is treated early enough, angioplasty often can cure the high blood pressure, said Dr. Olin. Angioplasty also can be performed in people with narrowing of the neck arteries who have symptoms. Many patients also take high blood pressure medicine or antiplatelet therapy, such as aspirin or prescription medications.

Untreated, FMD can lead to a tear in the artery and can be deadly.  FMD in the renal arteries on rare occasions can lead to permanent kidney damage.

Although it is unclear what causes FMD, about 10 to 12 percent of people with the condition have a close relative who has it, Dr. Olin said. “There are many, many unanswered questions about FMD,” said Dr. Olin. “We’re hopeful information gathered through the registry will help us answer those questions, spread the word about how common this condition is and help people get treatment earlier.”

About the International Symposium on Endovascular Therapy (ISET)
Begun in 1989 and led by acclaimed interventionist Barry Katzen, M.D., ISET is attended annually by physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET 2012 will take place Jan. 15–19 at the Fontainebleau Miami Beach. For more information, go to http://www.iset.org.

Editor’s note: Study numbers are current as of Jan. 8, 2012 and may change upon presentation at the ISET meeting.

Copies of ISET 2012 news releases are available online at www.ISETnews.org.

PATIENTS REPORT CONTROVERSIAL MULTIPLE SCLEROSIS TREATMENT IMPROVES THEIR LIVES

MIAMI BEACH, Fla. – Although using angioplasty to treat multiple sclerosis (MS) is highly controversial, sufferers often insist it helps – in some cases dramatically, such as allowing them to walk without a cane. Patients with less-severe MS also reported additional quality of life improvements, such as being able to talk more clearly, after having treatment to open blocked blood vessels in the chest and neck, according to research being presented at the 24^th annual International Symposium on Endovascular Therapy (ISET).

A controversial theory holds that MS symptoms may be caused by narrowed veins leading away from the brain, which interrupts blood flow between the brain and heart. This condition, called chronic cerebrospinal venous insufficiency (CCSVI), is treated with minimally invasive angioplasty to open up those narrowed veins. In the research being presented at ISET, more than 65 percent of patients treated for CCSVI report quality of life improvements three months after treatment.

“The patients reported improvement in common MS symptoms such as brain fog, frozen extremities, dizziness, bladder control and speech, and over time, they continued to improve,” said Marco Magnano, M.D., professor of interventional radiology at the Residency of Vascular Surgery of University of Catania, Sicily. “Although this could be due to the placebo effect, you have to wonder how that alone could help patients get out of the wheelchair, or forgo a cane or crutches.”

In the study, 170 patients were evaluated using the expanded disability status scale (EDSS), a standard method used to quantify the level of disability in MS patients. Using the EDSS, patients rank their symptoms from 0 to 10, with higher numbers indicating more severe disability. Prior to treatment, the patients in the study averaged 4.5, meaning they had some limitation of activity and were able to walk without resting for slightly more than 300 yards. Three months after treatment, they improved to an average of 4.0, meaning they were up and about 12 hours a day and able to walk without resting for more than 500 yards. The patients who initially scored higher on the disability scale were less likely to improve.

Because the EDSS focuses on physical abilities, the MS patients also filled out a questionnaire to gauge their quality of life, including participation in activities such as reading, recreation and socializing. Patients answered each of 16 quality of life questions with answers ranging from 1 (terrible) to 7 (delighted). Out of a total possible score of 112, patients overall improved from 64 before treatment to 70 after one month and 71 after three months. Six-month follow up in 77 patients suggests the benefits may wane, but scores remain better than they were before treatment.

“In about a quarter of the cases, the treated veins restenose – become reclogged – which correlates with symptoms worsening again and suggests this condition is valid,” said Dr. Magnano. “More studies are necessary, but it is certainly premature to discount this treatment for MS.”

About the International Symposium on Endovascular Therapy (ISET)
Begun in 1989 and led by acclaimed interventionist Barry Katzen, M.D., ISET is attended annually by physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET 2012 will take place Jan. 15–19 at the Fontainebleau Miami Beach. For more information, go to http://www.iset.org.

Editor’s note: Study numbers are current as of Jan. 8, 2012 and may change upon presentation at the ISET meeting.

Copies of ISET 2012 news releases are available online at www.ISETnews.org.

MICROSCOPIC SPONGE-TYPE PARTICLES ZAP NOSEBLEEDS

MIAMI BEACH, Fla. – Nonstop nosebleeds can be serious and frightening, often sending people to the emergency room, where their noses are packed with gauze. When that doesn’t work, nosebleeds can be halted by injecting microscopic particles – made of the same material as a kitchen sponge – into the arteries that supply the nose.  The more blood vessels blocked the better, suggests research being presented at the 24^th annual International Symposium on Endovascular Therapy (ISET).

Worldwide, 60 percent of people have suffered nosebleeds, 6 percent of them so severely that they sought medical treatment. These unstoppable nosebleeds are most likely to occur in people who have high blood pressure or are taking blood thinners. Severe anemia from blood loss can lead to complications such as heart attack. Typical nosebleed treatment is to temporarily pack the nose with gauze, inflate a balloon to stop the blood flow or cauterize the blood vessels inside the nose. If those treatments fail, the next options are surgery, or minimally invasive embolization, in which polyvinyl alcohol (PVA) particles are injected into the blood vessels to the nose.

In a study, 84 patients had one to four blood vessels embolized. Nosebleed recurrence rates decreased as more blood vessels were embolized: 2 of 8 (25 percent) who had one blood vessel treated experienced recurrence as did 5 of 35 (14 percent) who had two vessels treated and 2 of 32 (6 percent) who had three vessels treated. None of nine who had four vessels treated experienced a recurrence. Minor pain and complications increased with the numbers of vessels embolized, including mild facial pain, swelling and headache, but were temporary and were treated with pain medication.

“Embolization is less invasive than surgery and is very successful, taking the pressure off the fragile lining of the nose and allowing it to heal before the arteries eventually partially reopen,” said Colin P. Derdeyn, M.D., director of the Stroke and Cerebrovascular Center at Washington University School of Medicine, Barnes Jewish Hospital, St. Louis. “Our research suggests that the more vessels you embolize, the more successful the treatment.”

To embolize the blood vessels, an interventional radiologist threads a tiny tube called a catheter into a groin artery and advances it through the body to one or more of the four arteries that supply the nose, injecting the PVA particles.  The particles temporarily stop the blood flow, halting the nosebleed and allowing the area to heal. PVA has been used safely in the body medically for about 50 years.

About the International Symposium on Endovascular Therapy (ISET)
Begun in 1989 and led by acclaimed interventionist Barry Katzen, M.D., ISET is attended annually by physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET 2012 will take place Jan. 15–19 at the Fontainebleau Miami Beach. For more information, go to http://www.iset.org.

Editor’s note: Study numbers are current as of Jan. 8, 2012 and may change upon presentation at the ISET meeting.

Copies of ISET 2012 news releases are available online at www.ISETnews.org.

TUMOR-FREEZING TREATMENT GIVES OVARIAN CANCER PATIENTS EXTRA TIME

MIAMI BEACH, Fla. – Killing tumors by freezing them can add precious time to the lives of women with ovarian cancer that has spread to other parts of the body. Minimally invasive cryoablation extends lives and is cost-effective, according to a study being presented at the 4^th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).

Once the cancer has spread (metastasized) beyond the ovaries, it usually isn’t curable, but surgery is often used to remove the tumors and extend life. Depending on the location of the tumors, however, that may not be an option, especially if the patient has previously undergone surgery to remove the cancer. The study shows cryoablation may be used to kill these tumors with extreme cold, resulting in significant survival time.

The study included 21 patients whose tumors in the abdomen, liver, lung and bone could not be removed surgically. Cryoablation was used to treat 48 tumors, killing 47 of them (98 percent). From the time of diagnosis of metastatic disease, average patient survival time was more than four years and seven months. That’s significant because women whose tumors are not successfully removed surgically – which occurs in about 60 percent of cases, according to studies – typically survive from about seven months to 2 ½ years. On average, more than three years had transpired from the time of diagnosis to the first cryoablation treatment, meaning these women had already passed their expected survival time, and yet cryoablation was able to extend their survival even further. Some patients had multiple cryoablation treatments and of 41 procedures, there were three major complications (7 percent). The complications included two deaths that were attributed to the cancer, not to the procedure.

The study also determined the treatment was extremely cost-effective, costing an average of $26,806 per life year saved, well below the current standard of $100,000.

“This study adds to the evidence that cryoablation is an effective option for patients who can’t have surgery,” said study author Hyun J. Bang, M.D., a radiologist resident at Wayne State University/Detroit Medical Center. “This procedure is often overlooked, but based on the high survival rate, cost effectiveness, consistent local control and safety of the procedure, we should be taking a closer look at cryoablation as an option before these women enter the latter stages of their disease.”

In cryoablation, a small needle is placed through the skin into the tumor, which is located using imaging guidance. High pressure argon flows to the tip of the cryoprobe where it expands in an internal chamber, causing a powerful cooling effect on the outside of the probe. This allows for rapid ice formation, which freezes and kills tumor cells.

About the Symposium on Clinical Interventional Oncology (CIO)
North America’s largest interventional oncology meeting, the Symposium on Clinical Interventional Oncology (CIO) takes place Jan. 14-15 in Miami Beach, Fla., in collaboration with the 24-year-old International Symposium on Endovascular Therapy (ISET). CIO offers physicians in a variety of specialties the ideal opportunity to introduce the growing field of interventional oncology into their practice to update current practices with new information. For more about CIO and ISET, go to ISET.org/oncology.

Editor’s note: Study numbers are current as of Jan. 8, 2012 and may change upon presentation at the ISET meeting.

Copies of ISET 2012 news releases are available online at www.ISETnews.org.

Carotid Artery Stenting to Be Explored and Debated In-Depth at the International Symposium on Endovascular Therapy (ISET) 2012

MIAMI, Fla., November 28, 2011 – Among the featured topics at the 24^th annual International Symposium on Endovascular Therapy (ISET) will be carotid artery stenting (CAS), a procedure that has been the subject of continuing controversy. Some of the industry’s leading experts will discuss and debate the advantages and risks of CAS, carotid endarterectomy (CEA) and medical therapy at ISET 2012.

As one of the industry’s foremost meetings in the multidisciplinary field of peripheral and cardiac interventional medicine, ISET brings together physicians, surgeons, scientists, researchers and other professionals specializing in endovascular therapy. ISET 2012 will be held January 15–19 at the Fontainebleau Miami Beach, with continuing medical education (CME) accreditation provided by Complete Conference Management (CCM).

Carotid artery stenting will be covered in a number of talks on Monday, January 16, including during a session on stroke prevention and one that offers an in-depth look at the benefits of CAS.

Featured speakers include interventional cardiologist William A. Gray, M.D., director of endovascular services at NewYork-Presbyterian Hospital/Columbia University Medical Center, who has served as principal investigator for numerous clinical trials, including the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST). Gray will discuss the controversy surrounding carotid stenting in the post-CREST era and examine the effectiveness of carotid stenting in reducing the risk of stroke. He will also lead a debate on whether carotid stenting should be an alternative to CEA in standard-risk and high-risk asymptomatic patients.

Frank J. Veith, M.D., professor of surgery at New York University and the Cleveland Clinic, will explore which asymptomatic carotid stenoses should be treated, and will argue in a debate that most asymptomatic patients are best treated with medical therapy.

A few of the other presenters in the Carotid Artery Stenting In-Depth session include Klaus Mathias, M.D., of the University of Muenster and Academic Teaching Hospital of Dortmund, Germany; Gary Ansel, M.D., of Riverside Methodist Hospital, Ohio; Kenneth Rosenfield, M.D., of Massachusetts General Hospital; and L. Nelson “Nick” Hopkins, M.D., of University at Buffalo Neurosurgery. These noted experts will review the fundamental techniques and the role of experience in carotid stenting, complex carotid stenting and complications in carotid stenting. Others will address related topics during the session.

Carotid artery stenting is just one of the many subjects to be spotlighted during ISET 2012, which will provide a deep dive into the latest developments in endovascular therapy. The five-day meeting includes intensive one-day symposia, general and concurrent sessions, small-group case reviews and live case demonstrations, which will originate at clinical sites in Miami, New York and Leipzig, Germany. The live cases complement the on-site presentations by virtually transporting attendees into the procedure room.

ISET brings together practitioners in the fields of interventional radiology, vascular surgery, interventional cardiology and cardiothoracic surgery and others who specialize in treating cardiovascular disease. To view the full ISET 2012 program or to register online, please visit http://www.iset.org. To register by phone, call 888-480-2031 (or 410-480-5224for international callers).

About the International Symposium on Endovascular Therapy (ISET)
Begun in 1989 and led by acclaimed interventionist Barry Katzen, M.D., ISET is attended annually by physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET 2012 will take place January 15–19 at the Fontainebleau Miami Beach. For more information, go to http://www.iset.org.

About Complete Conference Management
Complete Conference Management (CCM) incorporates state-of-the-art technology to provide innovative learning experiences. CCM specializes in utilizing today’s advanced communication technology to design and deliver education in a dynamic format. CCM’s expertise includes facilitating the live broadcast of medical procedures from medical centers to meeting sites worldwide using the most sophisticated transmission methods available, simultaneous translation as well as audience response systems (ARS). Complete Conference Management is accredited by the Accreditation Council for Continuing Medical Education (ACCME^®) to provide continuing medical education for physicians. To learn more about CCM, go to http://www.ccmcme.com or call 888-334-7495.

Media Inquires:
Sara Conley
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
312-558-1770

For Immediate Release

Chronic Cerebrospinal Venous Insufficiency (CCSVI) to Be Spotlighted at the International Symposium on Endovascular Therapy (ISET) 2012

MIAMI, Fla., November 7, 2011 – Innovators in the field of endovascular therapy will explore the often-contentious topic of chronic cerebrospinal venous insufficiency (CCSVI), which is theorized to be a contributing factor in the development of multiple sclerosis (MS), at the 24^th annual International Symposium on Endovascular Therapy (ISET).

Recognized as one of the industry’s foremost meetings in the multidisciplinary field of cardiac and peripheral interventional medicine, the ISET meeting is attended by physicians, researchers, scientists and other professionals. ISET 2012 will take place at the Fontainebleau Miami Beach from January 15–19, with continuing medical education (CME) accreditation provided by Complete Conference Management (CCM).

Internationally acclaimed experts will discuss and debate the latest advances in CCSVI in a dedicated session on the morning of January 19. [S1] Vascular surgeon Paolo Zamboni, M.D., of the University of Ferrara, who first developed the theory behind CCSVI, will review new diagnostic methodologies for the disease. Zamboni pioneered the diagnosis and treatment of CCSVI – work that has been heralded by many, yet remains a controversial subject. Michael Dake, M.D., of the Stanford University Medical Center, who was the first surgeon to operate on CCSVI-related stenosis in the United States, will kick off the session by addressing the many unanswered questions in CCSVI today, and will close with an update on ongoing research initiatives.

Other participants in the CCSVI session include neurologist Jack Burks, M.D., of the Multiple Sclerosis Association of America (MSAA); Lindsay Machan, M.D., of the University of British Columbia; and Gary Siskin, M.D., of the Albany Medical Center. These noted experts will host talks on CCSVI collaboration, imaging evaluation of CCSVI patients, techniques and pitfalls of CCSVI intervention, the current status of CCSVI in Canada and showcase outcomes of a single center experience.

CCSVI is just one of the many topics featured during ISET 2012, which will provide a comprehensive overview of new developments in the area of endovascular therapy. The five-day meeting comprises intensive one-day symposia, a variety of general and concurrent sessions, and small-group case reviews. Teams at clinical sites in New York, Miami and Leipzig, Germany, will conduct live case demonstrations during which operators perform the latest procedures while offering step-by-step explanations for the audience. The live cases complement the lectures by virtually transporting attendees into the procedure room.

ISET brings together practitioners in the fields of interventional radiology, vascular surgery, interventional cardiology, cardiothoracic surgery and others who specialize in treating cardiovascular disease. To view the full ISET 2012 program and to register online, please visit http://www.iset.org. To register by phone, call 888-480-2031 (or 410-480-5224 for international callers).

About the International Symposium on Endovascular Therapy (ISET)
Begun in 1989 and led by acclaimed interventionist Barry Katzen, M.D., ISET is attended annually by physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET 2012 will take place January 15–19 at the Fontainebleau Miami Beach. For more information, go to http://www.iset.org.

About Complete Conference Management
Complete Conference Management (CCM) incorporates state-of-the-art technology to provide innovative learning experiences. CCM specializes in utilizing today’s advanced communication technology to design and deliver education in a dynamic format. CCM’s expertise includes facilitating the live broadcast of medical procedures from medical centers to meeting sites worldwide using the most sophisticated transmission methods available, simultaneous translation as well as audience response systems (ARS). Complete Conference Management is accredited by the Accreditation Council for Continuing Medical Education (ACCME^®) to provide continuing medical education for physicians. To learn more about CCM, go to http://www.ccmcme.com or call 888-334-7495.

Media Inquires:
Sara Conley
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
312-558-1770

For Immediate Release

“Extreme EVAR and TEVAR” a Hot Topic at The International Symposium on Endovascular Therapy (ISET) 2012

MIAMI BEACH, Fla., October 24, 2011 – Endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR) take center stage at the upcoming 24^th Annual International Symposium on Endovascular Therapy (ISET), which brings together physicians, scientists, researchers and industry professionals working in the multidisciplinary field of peripheral and cardiac interventional medicine. The meeting will be held January 15–19, 2012, at the Fontainebleau Miami Beach, with CME accreditation provided by Complete Conference Management (CCM).

World-renowned experts will tackle cutting-edge issues in EVAR and TEVAR during several dedicated sessions on January 17. Michael Dake, M.D. of Stanford University Medical Center, who performed the first EVAR in the United States in 1991, will speak about technology in support of the procedures and discuss where existing devices fall short of current needs. Vascular surgeon Frank Veith, M.D. of the Cleveland Clinic and British surgeon Roger Greenhalgh, M.D. will debate “Should EVAR Be the First Choice for Abdominal Aortic Aneurysm (AAA) Therapy?” ISET Course Director Barry Katzen, M.D. of Baptist Cardiac & Vascular Institute in Miami will discuss the pros and cons associated with the growing use of the transapical approach to the aorta.

Related talks will offer a thorough review of next-generation devices not yet approved in the United States; a hard look at devices newly released in the market, including snorkels, chimneys and periscopes; an examination of pre-close techniques for EVAR and TEVAR; and trial updates.

In addition to EVAR and TEVAR, ISET will cover all subjects pertaining to endovascular therapy. The five-day meeting presents intensive one-day symposia and general and concurrent sessions, as well as small-group case reviews. Live case demonstrations from clinical sites in Miami, New York and Leipzig, Germany – during which operators narrate their work with patients and take questions from panelists assembled in the ballroom of the Fontainebleau – will complement the lectures and give attendees the equivalent of a front-row seat in the procedure room. Physician attendees represent specialists in the fields of interventional radiology, interventional cardiology, vascular surgery, cardiothoracic surgery and others involved in the treatment of cardiovascular disease.

To view the complete ISET program and to register online, go to ISET.org. Phone registration is available at 888-480-2031 (or 410-480-5224 for international callers).

About the International Symposium on Endovascular Therapy (ISET)
Begun in 1989 and led by acclaimed interventionist Barry Katzen, M.D., ISET is attended annually by physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET 2012 will take place January 15–19 at the Fontainebleau Miami Beach. For more information, go to http://www.iset.org.

About Complete Conference Management
Complete Conference Management (CCM) incorporates state-of-the-art technology to provide innovative learning experiences. CCM specializes in utilizing today’s advanced communication technology to design and deliver education in a dynamic format. CCM’s expertise includes facilitating the live broadcast of medical procedures from medical centers to meeting sites worldwide using the most sophisticated transmission methods available, simultaneous translation as well as audience response systems (ARS). Complete Conference Management is accredited by the Accreditation Council for Continuing Medical Education (ACCME^®) to provide continuing medical education for physicians. To learn more about CCM, go to http://www.ccmcme.com or call 888-334-7495.

Media Inquiries
Sara Conley
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
312-558-1770